SL
Siren, L.L.C.
13F filer · CIK 0002005245Reported Aug 13, 2026
Net buyer this quarter
13F portfolio value$4.94BU.S. long equity reported on 13F
Positions11524 new · 9 closed
Net flow last quarter+$341MBuys minus sells
Top 10 positions weight44.6%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 13, 2026115 positions | |||||
| $527M | 10.66% | 7.87% | -11.6% | Q3 2024 | |
| $337M | 6.81% | 3.55% | -7.9% | Q3 2024 | |
| $209M | 4.23% | 3.65% | +1.4% | Q3 2024 | |
| $204M | 4.12% | 3.96% | +10.0% | Q1 2026 | |
| $193M | 3.91% | 3.67% | +9.2% | Q3 2024 | |
| $169M | 3.41% | 0.42% | -19.0% | Q3 2024 | |
| BTBCAXBicara Therapeutics Inc. | $166M | 3.37% | 8.50% | -3.5% | Q3 2024 |
| $140M | 2.83% | 1.22% | +6.2% | Q3 2024 | |
| $133M | 2.68% | 0.03% | Not reported | Q3 2024 | |
| $129M | 2.62% | 2.95% | -28.1% | Q3 2024 | |
| $126M | 2.55% | 1.65% | +56.6% | Q1 2025 | |
| $106M | 2.15% | 9.91% | Not reported | Q3 2024 | |
| $90.1M | 1.82% | 2.42% | +137.8% | Q1 2026 | |
| $86M | 1.74% | 1.10% | +18.3% | Q4 2024 | |
| $81.9M | 1.66% | 2.45% | New | Q2 2026 | |
| $79.6M | 1.61% | 1.36% | Not reported | Q3 2024 | |
| $76.8M | 1.55% | 7.32% | Not reported | Q3 2024 | |
| $76.8M | 1.55% | 0.73% | New | Q2 2026 | |
| $76.6M | 1.55% | 4.47% | New | Q2 2026 | |
| $74.6M | 1.51% | 1.91% | -19.5% | Q3 2024 | |
| $72M | 1.46% | 1.08% | +8.8% | Q2 2025 | |
| $68.3M | 1.38% | 1.67% | New | Q2 2026 | |
| $67.1M | 1.36% | 3.03% | +11.5% | Q3 2024 | |
| $66.8M | 1.35% | 1.06% | +54.4% | Q1 2026 | |
| $65.3M | 1.32% | 3.20% | Not reported | Q4 2024 | |
| $65M | 1.31% | 2.32% | -10.1% | Q1 2025 | |
| $64.7M | 1.31% | 0.61% | +23.6% | Q3 2024 | |
| $63.6M | 1.29% | 4.16% | -5.0% | Q4 2024 | |
| $60.8M | 1.23% | 5.55% | +2.1% | Q4 2025 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $53.2M | 1.08% | 1.34% | -25.4% | Q3 2024 |
| $48.8M | 0.99% | 1.71% | New | Q2 2026 | |
| $47.3M | 0.96% | 1.29% | -4.5% | Q3 2024 | |
| $46.9M | 0.95% | 0.41% | -34.3% | Q3 2025 | |
| $42.1M | 0.85% | 2.51% | -15.5% | Q3 2024 | |
| $39.3M | 0.80% | 1.79% | Not reported | Q4 2025 | |
| $36.4M | 0.74% | 2.34% | +13.7% | Q3 2024 | |
| $35.9M | 0.73% | 0.87% | Not reported | Q3 2024 | |
| $34.6M | 0.70% | 0.73% | Not reported | Q3 2024 | |
| $34.5M | 0.70% | 2.94% | +58.7% | Q3 2024 | |
| $34.4M | 0.70% | 0.03% | New | Q2 2026 | |
| $33.3M | 0.67% | 1.25% | Not reported | Q4 2024 | |
| $32.5M | 0.66% | 2.89% | Not reported | Q3 2024 | |
| $32.2M | 0.65% | 0.00% | +37.0% | Q3 2024 | |
| $30.5M | 0.62% | 0.63% | Not reported | Q4 2025 | |
| $28.7M | 0.58% | 1.59% | +37.5% | Q1 2026 | |
| $26.9M | 0.54% | 1.35% | +103.5% | Q1 2025 | |
| $26.7M | 0.54% | 1.34% | Not reported | Q3 2024 | |
| $26.6M | 0.54% | 1.33% | +20.4% | Q1 2026 | |
| $25.5M | 0.52% | 2.99% | +12.6% | Q1 2026 | |
| $25M | 0.51% | 4.02% | Not reported | Q4 2025 | |
| Q1 2026Reported May 14, 2026100 positions | |||||
| $532M | 14.75% | 9.09% | Not reported | Q3 2024 | |
| $265M | 7.36% | 3.88% | -3.0% | Q3 2024 | |
| $182M | 5.04% | 3.62% | +28.4% | Q3 2024 | |
| $140M | 3.87% | 4.12% | -2.2% | Q3 2024 | |
| $138M | 3.83% | 0.03% | -7.0% | Q3 2024 | |
| $118M | 3.28% | 3.92% | -30.7% | Q3 2024 | |
| BTBCAXBicara Therapeutics Inc. | $115M | 3.20% | 8.85% | +11.2% | Q3 2024 |
| $108M | 3.00% | 0.56% | -16.8% | Q3 2024 | |
| $101M | 2.81% | 1.15% | +7.7% | Q3 2024 | |
| $95.1M | 2.64% | 4.03% | New | Q1 2026 | |
| $76.7M | 2.13% | 1.36% | +62.2% | Q3 2024 | |
| $70.9M | 1.97% | 5.45% | +44.1% | Q4 2025 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $69.1M | 1.92% | 1.81% | +26.3% | Q3 2024 |
| $69.1M | 1.92% | 10.41% | +13.8% | Q3 2024 | |
| $65.8M | 1.82% | 1.00% | +4.9% | Q2 2025 | |
| $65M | 1.80% | 3.21% | -11.2% | Q4 2024 | |
| $65M | 1.80% | 2.40% | Not reported | Q3 2024 | |
| $64M | 1.78% | 0.62% | +23.2% | Q3 2025 | |
| $63.2M | 1.75% | 2.59% | Not reported | Q1 2025 | |
| $63.1M | 1.75% | 1.06% | +45.1% | Q1 2025 | |
| $55.4M | 1.53% | 7.82% | Not reported | Q3 2024 | |
| $48.1M | 1.33% | 4.45% | Not reported | Q4 2024 | |
| CPCNTACentessa Pharmaceuticals PLC | $41.8M | 1.16% | 0.68% | -73.8% | Q3 2024 |
| $41.3M | 1.14% | 1.04% | Not reported | Q4 2024 | |
| $40.5M | 1.12% | 0.50% | Not reported | Q3 2024 | |
| $40.4M | 1.12% | 1.35% | -36.4% | Q3 2024 | |
| $39.5M | 1.09% | 3.07% | -12.8% | Q3 2024 | |
| $38.8M | 1.08% | 0.63% | Not reported | Q4 2025 | |
| $38M | 1.05% | 2.90% | +197.6% | Q3 2024 | |
| $35.8M | 0.99% | 7.84% | +57.5% | Q4 2025 | |
| $32.1M | 0.89% | 1.80% | +243.3% | Q4 2025 | |
| $30.9M | 0.86% | 2.97% | Not reported | Q3 2024 | |
| $29.3M | 0.81% | 1.23% | New | Q1 2026 | |
| $26.8M | 0.74% | 0.88% | Not reported | Q3 2024 | |
| $24.2M | 0.67% | 0.73% | -4.6% | Q3 2024 | |
| $23.3M | 0.65% | 1.49% | New | Q1 2026 | |
| $22.2M | 0.62% | 3.94% | +187.3% | Q4 2025 | |
| $21.9M | 0.61% | 2.65% | New | Q1 2026 | |
| $21.3M | 0.59% | 1.39% | -21.9% | Q4 2024 | |
| $20.1M | 0.56% | 1.34% | -9.5% | Q3 2024 | |
| $18.9M | 0.52% | 0.00% | +217.4% | Q3 2024 | |
| $18M | 0.50% | 3.53% | +20.5% | Q4 2025 | |
| $17.8M | 0.49% | 1.27% | Not reported | Q3 2024 | |
| $17.4M | 0.48% | 0.88% | New | Q1 2026 | |
| $17.1M | 0.47% | 1.11% | New | Q1 2026 | |
| $17M | 0.47% | 1.94% | Not reported | Q3 2024 | |
| $16.6M | 0.46% | 4.67% | +35.1% | Q3 2024 | |
| $16.4M | 0.45% | 1.59% | Not reported | Q3 2025 | |
| $16.3M | 0.45% | 2.03% | New | Q1 2026 | |
| $15.5M | 0.43% | 0.00% | +137.7% | Q3 2024 | |
| Q4 2025Reported Feb 13, 2026113 positions | |||||
| $477M | 14.22% | 9.98% | +17.0% | Q3 2024 | |
| $256M | 7.63% | 4.04% | -4.1% | Q3 2024 | |
| $152M | 4.53% | 0.03% | +1.4% | Q3 2024 | |
| $112M | 3.35% | 4.26% | +16.2% | Q3 2024 | |
| $106M | 3.17% | 0.68% | +27.9% | Q3 2024 | |
| CPCNTACentessa Pharmaceuticals PLC | $101M | 3.00% | 2.70% | +24.8% | Q3 2024 |
| $99.6M | 2.97% | 1.09% | -43.8% | Q3 2024 | |
| BTBCAXBicara Therapeutics Inc. | $87.8M | 2.62% | 9.22% | Not reported | Q3 2024 |
| $82.5M | 2.46% | 4.06% | New | Q4 2025 | |
| $78.5M | 2.34% | 2.61% | +8.2% | Q1 2025 | |
| $75M | 2.24% | 0.51% | +5.1% | Q3 2025 | |
| $72.3M | 2.16% | 6.01% | +38.8% | Q3 2024 | |
| $71.7M | 2.14% | 2.40% | +3.3% | Q3 2024 | |
| $71.3M | 2.13% | 3.81% | Not reported | Q4 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $70.2M | 2.09% | 1.58% | -10.7% | Q3 2024 |
| $68.5M | 2.04% | 2.12% | -25.9% | Q3 2024 | |
| APAPLSApellis Pharmaceuticals, Inc. | $64.8M | 1.93% | 2.04% | Not reported | Q3 2024 |
| $57.9M | 1.73% | 1.01% | -5.5% | Q2 2025 | |
| $55.8M | 1.66% | 4.46% | -9.2% | Q4 2024 | |
| $55.7M | 1.66% | 3.55% | -8.0% | Q3 2024 | |
| $53.5M | 1.60% | 0.74% | Not reported | Q1 2025 | |
| $50.3M | 1.50% | 0.38% | Not reported | Q3 2024 | |
| RTRAPTRAPT Therapeutics, Inc. | $46.6M | 1.39% | 4.96% | +136.9% | Q3 2025 |
| $46M | 1.37% | 2.97% | Not reported | Q3 2024 | |
| $44.8M | 1.34% | 10.64% | Not reported | Q3 2024 | |
| $44.2M | 1.32% | 2.25% | New | Q4 2025 | |
| $43.4M | 1.29% | 9.74% | +3.7% | Q3 2024 | |
| $41.7M | 1.24% | 1.31% | -33.7% | Q3 2024 | |
| $36.4M | 1.09% | 1.02% | Not reported | Q3 2024 | |
| $35.6M | 1.06% | 1.10% | New | Q4 2025 | |
| $32.6M | 0.97% | 3.08% | Not reported | Q3 2024 | |
| $30.1M | 0.90% | 4.98% | New | Q4 2025 | |
| $28.6M | 0.85% | 1.78% | -9.9% | Q4 2024 | |
| $26.8M | 0.80% | 1.05% | +122.1% | Q4 2024 | |
| $25.4M | 0.76% | 0.86% | New | Q4 2025 | |
| $23.1M | 0.69% | 0.89% | +70.0% | Q3 2024 | |
| $22.3M | 0.67% | 0.77% | Not reported | Q3 2024 | |
| $22.1M | 0.66% | 2.93% | New | Q4 2025 | |
| $21.5M | 0.64% | 1.48% | -32.8% | Q3 2024 | |
| $17.7M | 0.53% | 2.05% | Not reported | Q3 2024 | |
| $17.6M | 0.52% | 0.70% | Not reported | Q3 2024 | |
| $16.1M | 0.48% | 2.23% | Not reported | Q3 2024 | |
| $16M | 0.48% | 1.08% | -25.4% | Q4 2024 | |
| $14.3M | 0.43% | 2.90% | Not reported | Q4 2024 | |
| $13.9M | 0.41% | 3.17% | New | Q4 2025 | |
| $12.4M | 0.37% | 1.98% | Not reported | Q3 2024 | |
| $12.3M | 0.37% | 0.67% | -7.7% | Q1 2025 | |
| $12M | 0.36% | 4.44% | New | Q4 2025 | |
| $11.9M | 0.36% | 1.13% | +157.3% | Q3 2025 | |
| $11.9M | 0.35% | 0.00% | -12.0% | Q3 2024 | |
| Q3 2025Reported Nov 13, 2025115 positions | |||||
| $344M | 13.48% | 9.33% | Not reported | Q3 2024 | |
| $194M | 7.59% | 4.78% | Not reported | Q3 2024 | |
| $168M | 6.57% | 0.03% | -3.3% | Q3 2024 | |
| $92.1M | 3.60% | 1.97% | Not reported | Q3 2024 | |
| BTBCAXBicara Therapeutics Inc. | $82.4M | 3.22% | 9.55% | Not reported | Q3 2024 |
| CPCNTACentessa Pharmaceuticals PLC | $78.3M | 3.06% | 2.40% | -6.7% | Q3 2024 |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $70.3M | 2.75% | 1.79% | Not reported | Q3 2024 |
| $63.2M | 2.47% | 3.68% | +23.3% | Q3 2024 | |
| $60.4M | 2.36% | 2.61% | -16.9% | Q1 2025 | |
| $59.8M | 2.34% | 3.32% | -2.2% | Q3 2024 | |
| APAPLSApellis Pharmaceuticals, Inc. | $58.3M | 2.28% | 2.04% | Not reported | Q3 2024 |
| ABRNAMAvidity Biosciences, Inc. | $56M | 2.19% | 0.88% | +15.8% | Q3 2024 |
| $52.8M | 2.07% | 4.08% | Not reported | Q4 2024 | |
| $52.5M | 2.06% | 10.64% | Not reported | Q3 2024 | |
| $50.5M | 1.98% | 0.75% | +22.0% | Q1 2025 | |
| $49.4M | 1.93% | 5.27% | +74.8% | Q3 2024 | |
| $48.7M | 1.91% | 0.55% | +11.2% | Q3 2024 | |
| $46.9M | 1.83% | 0.39% | -4.1% | Q3 2024 | |
| $45.8M | 1.79% | 5.35% | New | Q3 2025 | |
| $45.8M | 1.79% | 9.52% | Not reported | Q3 2024 | |
| $41.4M | 1.62% | 4.93% | Not reported | Q4 2024 | |
| $39.6M | 1.55% | 2.72% | +80.6% | Q3 2024 | |
| $36M | 1.41% | 4.02% | Not reported | Q3 2024 | |
| $34M | 1.33% | 2.97% | Not reported | Q3 2024 | |
| $32.6M | 1.28% | 1.05% | Not reported | Q3 2024 | |
| STSLNOSoleno Therapeutics Inc | $31.6M | 1.24% | 0.87% | Not reported | Q4 2024 |
| $31.3M | 1.22% | 2.21% | +178.4% | Q3 2024 | |
| $28.8M | 1.12% | 0.56% | New | Q3 2025 | |
| $27.1M | 1.06% | 2.31% | Not reported | Q3 2024 | |
| $26.4M | 1.03% | 0.77% | +214.0% | Q3 2024 | |
| $24.8M | 0.97% | 1.23% | +101.8% | Q2 2025 | |
| $23.2M | 0.91% | 1.98% | -35.6% | Q4 2024 | |
| $21.8M | 0.85% | 0.68% | -35.9% | Q3 2024 | |
| $20.1M | 0.78% | 4.46% | Not reported | Q3 2024 | |
| $19.1M | 0.75% | 3.09% | Not reported | Q3 2024 | |
| $16.1M | 0.63% | 0.71% | Not reported | Q3 2024 | |
| $16.1M | 0.63% | 0.44% | New | Q3 2025 | |
| $15.6M | 0.61% | 2.90% | Not reported | Q4 2024 | |
| $15.1M | 0.59% | 2.05% | Not reported | Q3 2024 | |
| RTRAPTRAPT Therapeutics, Inc. | $15M | 0.59% | 3.51% | New | Q3 2025 |
| $14.8M | 0.58% | 1.46% | Not reported | Q4 2024 | |
| $13.7M | 0.54% | 2.25% | Not reported | Q3 2024 | |
| $12.9M | 0.51% | 1.71% | Not reported | Q2 2025 | |
| $12.8M | 0.50% | 0.00% | +3.5% | Q3 2024 | |
| $12.1M | 0.47% | 1.04% | Not reported | Q3 2024 | |
| $11.9M | 0.47% | 0.56% | Not reported | Q3 2024 | |
| $10.5M | 0.41% | 0.05% | Not reported | Q3 2024 | |
| $9.56M | 0.37% | 0.73% | Not reported | Q1 2025 | |
| $9.07M | 0.35% | 0.01% | Not reported | Q3 2024 | |
| $8.88M | 0.35% | 0.00% | +6.2% | Q3 2024 | |
Premium opens every quarter this fund has filed